InvestorsHub Logo
Followers 617
Posts 27445
Boards Moderated 3
Alias Born 11/16/2007

Re: Unattached post# 291202

Monday, 04/06/2020 9:08:55 PM

Monday, April 06, 2020 9:08:55 PM

Post# of 403478
I don't see the company releasing drug for right to try. They need to go straight to a clinical trial and should be able to easily if Brilacidin shows successful results in human lung cells. FDA is in a hurry to find something workable.

Imagine a patient passes away with right to try...was the patient too far along, or was it an issue with the drug. Right to try muddies the waters and that is why most companies don't give out drug for right to try.

And, with limited supply since most is needed in trials, how do you choose which patient gets a shot at it?

The clinical trials will be pushed ahead quickly and many patients will effectively have the same as right to try due to bypassing all the usual redtape. I don't believe it would matter if it was a ph1. The drug either works in humans or it doesn't. With a full trial we'll get our answer quickly without all the nonsense back and forth about whether or not it works that will come out of a single case right to try patient.

I could easily be wrong.






Message in reply to:

If the dosage amount changes from what's been tried would there need to be a phase 1 for COVID before a Right-To-Try

"Immediate next steps include conducting studies in human lung cells, exploring dosing and evaluating the drug’s effect on the viral envelope."















To follow KarinCA, click here then click "Follow This Member" under my photo.

Be kinder than necessary, for everyone you meet is fighting some kind of battle.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News